About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2023-07-06
Henlius Welcomed SAB Member Alberto Mantovani to its Shanghai Innovation Centre
2023-07-03
Henlius Forecasts Profit in 2023 H1: Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle
2023-06-28
Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of 2023
2023-06-26
Henlius Immune Checkpoints Inhibitor Anti-CTLA-4 mAb Received IND Approval for the Treatment of HCC
2023-06-15
First Patient Dosed of Phase 2 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Metastatic Colorectal Cancer Patients
2023-06-12
Henlius Shines for Five Consecutive Years at BIO International Convention
2023-06-06
Results From the Phase 2 Clinical Trial of HLX07 for the Treatment of ESCC Released at 2023 ASCO
2023-06-06
Results From the Phase 2 Clinical Trial of Henlius BRAFV600E Inhibitor HLX208 for the Treatment of LCH and/or ECD Released at 2023 ASCO Annual Meeting
2023-05-26
2023 ASCO Annual Meeting Released Clinical Data of Two Henlius Trials
1
2
3
4
5
6
7
8
